A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.

Item
http://www.wikidata.org/entity/Q33335224
Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomasEmerging DNA topisomerase inhibitors as anticancer drugs.The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for hPixantrone: a promising drug in the treatment of non-Hodgkin lymphomas.Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.Pixantrone: merging safety with efficacy.Binding of pixantrone to DNA at CpA dinucleotide sequences and bulge structures.Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.Reversible and formaldehyde-mediated covalent binding of a bis-amino mitoxantrone analogue to DNA.Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells
P2860

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.

Item
http://www.wikidata.org/entity/Q33335224
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
A clinical phase I and pharmac ...... tered intravenously, 3 weekly.
@ast
A clinical phase I and pharmac ...... tered intravenously, 3 weekly.
@en
A clinical phase I and pharmac ...... tered intravenously, 3 weekly.
@nl
type
label
A clinical phase I and pharmac ...... tered intravenously, 3 weekly.
@ast
A clinical phase I and pharmac ...... tered intravenously, 3 weekly.
@en
A clinical phase I and pharmac ...... tered intravenously, 3 weekly.
@nl
prefLabel
A clinical phase I and pharmac ...... tered intravenously, 3 weekly.
@ast
A clinical phase I and pharmac ...... tered intravenously, 3 weekly.
@en
A clinical phase I and pharmac ...... tered intravenously, 3 weekly.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
A clinical phase I and pharmac ...... tered intravenously, 3 weekly.
@en
P2093
P304
P31
P356
10.1016/S0959-8049(00)00342-7
P433
P478
P577
P698